KEGG   DRUG: Gemtuzumab ozogamicinHelp
Entry
D03259                      Drug                                   

Name
Gemtuzumab ozogamicin (USAN);
Gemtuzumab ozogamicin (genetical recombination) (JAN);
Gemtuzumab (INN);
Mylotarg (TN)
Product
Class
Cyp substrate
 DG01633  CYP3A substrate
Remark
Therapeutic category: 
ATC code: 
Chemical group: 
Efficacy
Antineoplastic, Anti-CD33 antibody
  Disease
Acute myeloid leukemia [DS:H00003]
Comment
Monoclonal antibody
Withdrawn from the US market
Target
CD33 [HSA:945] [KO:K06473]
  Pathway
Hematopoietic cell lineage
Metabolism
Enzyme: CYP3A4 [HSA:1576]
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC05 Gemtuzumab ozogamicin
      D03259  Gemtuzumab ozogamicin (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   423  Antibiotics
    4239  Others
     D03259  Gemtuzumab ozogamicin (USAN); Gemtuzumab ozogamicin (genetical recombination) (JAN); Gemtuzumab (INN)
Target-based classification of drugs [BR:br08310]
 Others
  Cellular antigens
   CD33
    Gemtuzumab
     D03259  Gemtuzumab ozogamicin (USAN)
Cytochrome P450 interactions [BR:br08309]
 CYP substrates
  CYP3A4
   Gemtuzumab
    D03259  Gemtuzumab ozogamicin (USAN)
Antineoplastics [br08340.html]
 D03259
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D03259
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D03259
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D03259
Orphan drugs in the USA [br08355.html]
 Orphan drugs in the USA
  D03259
BRITE hierarchy
Other DBs
CAS: 
220578-59-6
PubChem: 
DrugBank: 
NIKKAJI: 
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system